Encyclopedia

  • Biotin-functionalized targeting anti-tumor complex based on β-cyclodextrin and methotrexate
  • Add time:08/21/2019         Source:sciencedirect.com

    The design and construction of tumor-targeted drug delivery systems provide us a facile method to treat cancers selectively. In this work, a biotin-targeting inclusion complex based on β-cyclodextrin and methotrexate was designed and prepared successfully. Compared with other delivery systems, in addition to hypotoxicity and high bioavailability, this targeting inclusion complex also has relatively high drug conjugation rate and with the linkage of more than 1/5 targeting ligand. In order to verify physical and chemical properties of this system, a series of experiments were carried out. The results showed that methotrexate-cyclodextrin conjugate could form very stable inclusion complex with biotin-adamantine conjugate. Water solubility of methotrexate was improved greatly by the introduction of β-cyclodextrin. In addition, according to MTT assay results, anticancer activity of amantadine-biotin/methotrexate-cyclodextrin inclusion complex against three human cancer cell lines was higher than methotrexate-cyclodextrin conjugate and free methotrexate. Further, targeting effect of the inclusion complex was also confirmed by the addition of biotin with different concentrations to make biotin receptors be saturated to vary degrees previously, which also provides a strategy for the verification of tumor-targeting of biotin. Serum stability test and drug release test also confirmed that this biotin-targeting inclusion complex was expected to be applied in the field of biomedicine for further research.

    We also recommend Trading Suppliers and Manufacturers of Methotrexate sodium (cas 15475-56-6). Pls Click Website Link as below: cas 15475-56-6 suppliers


    Prev:Curcumin ameliorates the targeted delivery of methotrexate intercalated montmorillonite clay to cancer cells
    Next: Evaluation of topical human platelet lysate versus topical clobetasol in management of methotrexate-induced oral ulceration in rheumatoid arthritis patients: Randomized-controlled clinical trial)

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View